CA2908577C - Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity - Google Patents

Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity Download PDF

Info

Publication number
CA2908577C
CA2908577C CA2908577A CA2908577A CA2908577C CA 2908577 C CA2908577 C CA 2908577C CA 2908577 A CA2908577 A CA 2908577A CA 2908577 A CA2908577 A CA 2908577A CA 2908577 C CA2908577 C CA 2908577C
Authority
CA
Canada
Prior art keywords
benzimidazol
diene
androsta
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2908577A
Other languages
English (en)
French (fr)
Other versions
CA2908577A1 (en
Inventor
Vincent C.O. Njar
Purushottamachar Puranik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Original Assignee
University of Maryland Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51659362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2908577(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Maryland Baltimore filed Critical University of Maryland Baltimore
Priority to CA3151555A priority Critical patent/CA3151555A1/en
Publication of CA2908577A1 publication Critical patent/CA2908577A1/en
Application granted granted Critical
Publication of CA2908577C publication Critical patent/CA2908577C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2908577A 2013-04-04 2014-04-04 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity Active CA2908577C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3151555A CA3151555A1 (en) 2013-04-04 2014-04-04 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361808345P 2013-04-04 2013-04-04
US61/808,345 2013-04-04
US201361808902P 2013-04-05 2013-04-05
US61/808,902 2013-04-05
PCT/US2014/033063 WO2014165815A2 (en) 2013-04-04 2014-04-04 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3151555A Division CA3151555A1 (en) 2013-04-04 2014-04-04 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity

Publications (2)

Publication Number Publication Date
CA2908577A1 CA2908577A1 (en) 2014-10-09
CA2908577C true CA2908577C (en) 2022-05-31

Family

ID=51659362

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2908577A Active CA2908577C (en) 2013-04-04 2014-04-04 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
CA3151555A Pending CA3151555A1 (en) 2013-04-04 2014-04-04 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3151555A Pending CA3151555A1 (en) 2013-04-04 2014-04-04 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity

Country Status (6)

Country Link
US (2) US9694005B2 (https=)
EP (2) EP2991644B1 (https=)
JP (1) JP6417392B2 (https=)
AU (1) AU2014247941C1 (https=)
CA (2) CA2908577C (https=)
WO (1) WO2014165815A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675289B2 (en) 2014-10-02 2020-06-09 University Of Maryland, Baltimore Methods of treating pancreatic cancer
WO2017201683A1 (en) * 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
EP3474848A4 (en) * 2016-06-22 2020-04-15 University of Maryland, Baltimore PROCESS FOR PRODUCING NEW GALETERONE ANALOGS AND USES THEREOF
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN106902112B (zh) * 2017-03-07 2019-06-04 中国医学科学院医药生物技术研究所 Imb-a6作为雄激素受体拮抗剂的应用
CN111943889B (zh) * 2020-07-24 2022-07-22 中国医学科学院医药生物技术研究所 一种双芳香基胺类化合物及其制备方法和应用
CN116444599B (zh) * 2022-01-07 2026-02-03 中国科学院上海药物研究所 甾体类化合物及制备方法和用途
WO2024064026A1 (en) * 2022-09-19 2024-03-28 Alterome Therapeutics, Inc. Akt1 modulators
IL319572A (en) 2022-09-26 2025-05-01 Alterome Therapeutics Inc AKT1 modulators
EP4608841A1 (en) * 2022-10-25 2025-09-03 University of Maryland, Baltimore Salts of galeterone and salts of next generation galeterone analogs, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129379A (en) 1910-10-18 1910-11-22 John Clarence Bisland Hoe
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
DK40192D0 (da) 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
AU2006218711B2 (en) * 2005-03-02 2010-11-11 University Of Maryland, Baltimore Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8188131B2 (en) 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
CN102686600A (zh) * 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
WO2010091299A2 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel combination cancer therapies
CN103813794A (zh) * 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
RU2015137617A (ru) * 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение

Also Published As

Publication number Publication date
US20170266181A1 (en) 2017-09-21
US10617685B2 (en) 2020-04-14
WO2014165815A3 (en) 2014-12-31
EP3514147A1 (en) 2019-07-24
EP2991644B1 (en) 2020-03-25
EP3514147B1 (en) 2022-08-03
AU2014247941C1 (en) 2019-10-31
CA2908577A1 (en) 2014-10-09
US20160038476A1 (en) 2016-02-11
JP6417392B2 (ja) 2018-11-07
WO2014165815A2 (en) 2014-10-09
US9694005B2 (en) 2017-07-04
CA3151555A1 (en) 2014-10-09
JP2016515630A (ja) 2016-05-30
AU2014247941B2 (en) 2017-04-27
EP2991644A2 (en) 2016-03-09
EP2991644A4 (en) 2017-02-08
AU2014247941A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
CA2908577C (en) Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
US9439912B2 (en) Androgen receptor down-regulating agents and uses thereof
EP3459925A1 (en) Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative
US20170273922A1 (en) Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
US7728150B2 (en) Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
WO1992012144A1 (en) Condensed benzoxa ring compound, production thereof, and pharmaceutical composition containing the same
EP3571183B1 (en) 3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer
WO2018175965A1 (en) Antiestrogens for cancer therapy
EP2493302A1 (en) Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
CN110615774B (zh) 具有抗炎活性的苄基哌嗪类化合物、制法及医药用途
US9650382B2 (en) Heteroarylamide derivatives having antiandrogenic properties
HK1201838B (en) Novel heteroarylamide derivatives having antiandrogenic properties

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190328

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328